Bently to Release Three Drugs on the Spanish Market

Bentley Pharmaceuticals Inc. recently announced that its Spanish subsidiary, Laboratorios Belmac, has entered into a supply agreement with Valpharma SA whereby Laboratorios Belmac will register and commercialize in Spain, extended release dosage formulations of diltiazem, pentoxifylline and ibuprofen 800mg.

Diltiazem is a leading calcium channel blocker used in the treatment of cardiovascular disease, pentoxifylline is a well-established peripheral vaso-dialator for the treatment of chronic peripheral arterial disease, and high dose ibuprofen (800mg) is an NSAID analgesic useful to relieve pain and inflammation in a number of conditions.

Bentley Pharmaceuticals develops drug delivery technology to provide treatment for cardiovascular, gastrointestinal, neurological and infectious diseases.

For more information: Elaine Melia, Bentley Pharmaceuticals. Tel: 813-286-4401.